Content about Watson Pharmaceuticals

December 15, 2010

Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

MORRISTOWN, N.J. — Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

Watson announced Tuesday that it had filed an application with the Food and Drug Administration seeking approval for hydromorphone hydrochloride extended-release tablets in the 8-mg, 12-mg and 16-mg strengths. The drug is a generic version of Mallinckrodt’s Exalgo.

December 13, 2010

Drug maker Shire has filed a patent infringement suit against Watson Pharmaceuticals and Impax Labs in response to their attempt to win approval from the Food and Drug Administration for a generic version of a Shire drug.

DUBLIN — Drug maker Shire has filed a patent infringement suit against Watson Pharmaceuticals and Impax Labs in response to their attempt to win approval from the Food and Drug Administration for a generic version of a Shire drug.

Shire announced that it had filed the suit in the U.S. District Court for the Northern District of California following the two generic drug makers’ filing of an approval application for guanfacine hydrochloride, a version of Shire’s Intuniv, used to treat hypertension.

December 7, 2010

U.S. generic drug maker Watson Pharmaceuticals and Indian drug maker Natco Pharma will work together to develop and commercialize a generic drug used for bone marrow disorders, the two companies said Tuesday.

MORRISTOWN, N.J. — U.S. generic drug maker Watson Pharmaceuticals and Indian drug maker Natco Pharma will work together to develop and commercialize a generic drug used for bone marrow disorders, the two companies said Tuesday.

The agreement concerns lenalidomide tablets in the 5-mg, 10-mg, 15-mg and 25-mg strengths. The drug is a generic version of Celgene’s Revlimid, used to treat the plasma cell cancer multiple myeloma and myelodysplastic syndrome. Myelodysplastic syndrome results from the bone marrow producing blood cells that are misshapen.

December 6, 2010

An investigational drug made by Watson Pharmaceuticals and Columbia Labs reduced the risk of premature birth, according to results of late-stage clinical trial.

MORRISTOWN, N.J. — An investigational drug made by Watson Pharmaceuticals and Columbia Labs reduced the risk of premature birth, according to results of a late-stage clinical trial.

The two companies announced results Monday of a phase-3 trial of Prochieve (progesterone), a vaginal gel, saying that it produced a significant reduction in the number of preterm births. The trial was conducted under a collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health.

December 1, 2010

Drug maker Watson Pharmaceuticals has made an emergency oral contraceptive available by prescription in the United States, the company said Wednesday.

MORRISTOWN, N.J. — Drug maker Watson Pharmaceuticals has made an emergency oral contraceptive available by prescription in the United States, the company said Wednesday.

Watson announced the launch of Ella (ulipristal acetate) in the 30-mg dose, designed to prevent pregnancy up to five days after unprotected sex or failure of other contraceptives. The drug is designed to delay ovulation for five days, the amount of time that sperm can survive in the female genital tract.

November 3, 2010

Sales for generic drug maker Watson Pharmaceuticals grew 33%, to $882.4 million, in third quarter...

MORRISTOWN, N.J. Sales for generic drug maker Watson Pharmaceuticals grew 33%, to $882.4 million, in third quarter 2010, according to an earnings report released Thursday.

 

The sales figure for the current quarter compared with $662.1 million in third quarter 2009. Profits were $105.9 million, compared with $90 million in third quarter 2009.

 

 

“Watson delivered another quarter of strong financial results and continued progress against our strategic objectives,” Watson president and CEO Paul Bisaro said.

November 1, 2010

Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used to treat attention deficit hyperactivity disorder, Watson said Tuesday.

Watson entered an agreement with Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to distribute an authorized generic of Concerta (methylphenidate hydrochloride) extended-release tablets. An authorized generic is a branded drug sold under its generic name, usually by a third-party company.

October 14, 2010

The Food and Drug Administration has approved a Watson Pharmaceuticals generic drug for treating high...

MORRISTOWN, N.J. The Food and Drug Administration has approved a Watson Pharmaceuticals generic drug for treating high blood pressure, Watson said Friday.

 

The company announced the FDA approval of amlodipine besylate and benazepril capsules in the 5/20-mg, 10/20-mg, 2.5/10-mg and 5/10-mg strengths.

 

 

The drug is a generic version of Novartis’ Lotrel. Branded and generic versions of the drug had sales of around $1.05 billion during the 12-month period ended in June, according to IMS Health.

 

October 6, 2010

Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller,...

MORRISTOWN, N.J. Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller, Watson said Thursday.

 

The generic drug maker said its subsidiary, Watson Labs, had received a royalty-free license to Endo’s patents covering the extended-release painkiller Opana ER (oxymorphone).

 

 

Watson will have the right to launch its version of the drug in September 2012. Other details of the settlement were not disclosed, Watson said.

 

October 4, 2010

Generic drug maker Watson Pharmaceuticals is seeking approval for a generic treatment for Parkinson’s disease,...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals is seeking approval for a generic treatment for Parkinson’s disease, prompting a lawsuit from the drug’s manufacturer.

 

Watson said Tuesday that Watson Labs, a subsidiary of the company, had filed for approval for rasagiline mesylate tablets, a treatment for Parkinson’s used either alone or with the drug levodopa. The drug is a generic version of Teva Neuroscience’s Azilect.

 

 

September 26, 2010

Greenstone announced the launch of an authorized generic version of the Alzheimer’s disease drug Aricept...

September 7, 2010

The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals,...

MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.

 

Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.

 

 

September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

August 15, 2010

A lot of generic drug companies have conducted business in the branded drug market on...

SOMERSET, N.J. A lot of generic drug companies have conducted business in the branded drug market on the side for a long time, with Teva Pharmaceutical Industries and Watson Pharmaceuticals standing out as good examples. But lately, some branded drug companies have sought to get into generics as well.

 

Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda A.B., recently decided to create its own generics subsidiary, calling it Wallace Pharmaceuticals, senior marketing director John White told Drug Store News.

 

August 9, 2010

Generic drug maker Watson Pharmaceuticals posted strong sales for second quarter 2010, according to an...

August 3, 2010

Generic drug maker Watson Pharmaceuticals has appointed two new executives this week....

July 14, 2010

Watson Pharmaceuticals will work with a venture-backed firm to develop a biosimilar treatment for female...

July 12, 2010

Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of a kidney disease treatment made by Genzyme, Watson said Monday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for sevelamer carbonate for oral suspension. The drug is a generic version of Genzyme’s Renvela, used to control serum phosphorus in patients with chronic kidney disease who are on dialysis.

 

July 5, 2010

The Food and Drug Administration has approved a drug made by Watson Pharmaceuticals for treating...

June 30, 2010

Watson Pharmaceuticals has launched a generic version of a drug used to treat dementia under...

June 23, 2010

The Food and Drug Administration has given tentative approval to Watson Pharmaceuticals for a generic...

May 25, 2010

Generic drug maker Watson Pharmaceuticals is challenging the patent on a drug for treating kidney...

May 24, 2010

Teva Pharmaceuticals has introduced a generic version of a drug for genital herpes, shingles and...

May 19, 2010

A subsidiary of generic drug maker Watson Pharmaceuticals has launched a version of a cholesterol-lowering...

May 9, 2010

Watson Pharmaceuticals had revenues of $856.5 million in the first quarter of this year, a...